Search Results

You are looking at 211 - 220 of 858 items for :

  • Refine by Access: All x
Clear All
Full access

Testicular Cancer

Robert J. Motzer, Neeraj Agarwal, Clair Beard, Sam Bhayani, Graeme B. Bolger, Mark K. Buyyounouski, Michael A. Carducci, Sam S. Chang, Toni K. Choueiri, Shilpa Gupta, Steven L. Hancock, Gary R. Hudes, Eric Jonasch, Timothy M. Kuzel, Clayton Lau, Ellis G. Levine, Daniel W. Lin, Kim A. Margolin, M. Dror Michaelson, Thomas Olencki, Roberto Pili, Thomas W. Ratliff, Bruce G. Redman, Cary N. Robertson, Charles J. Ryan, Joel Sheinfeld, Jue Wang, and Richard B. Wilder

useful in monitoring metastatic seminomas, because elevated marker levels is the early sign of relapse. LDH is a less-specific marker than AFP and β-HCG. AFP is a serum tumor marker produced by nonseminomatous cells (embryonal carcinoma, yolk-sac tumor

Full access

The NCCN 2021 Virtual Congress: Hematologic Malignancies

Robert W. Carlson

Lymphoma,” and “Updates in the Management of Early-Stage Diffuse Large B-Cell Lymphoma.” Additional sessions focused on updates in the management of relapsed/refractory mantle call lymphoma, optimizing therapy for relapsed/refractory diffuse large B

Full access

Letter to the Editor: No Evidence to Promote Interim FDG-PET Adapted Therapy in the NCCN Guidelines for Hodgkin Lymphoma

Hugo J.A. Adams and Thomas C. Kwee

interim FDG-PET results demonstrated markedly increased relapse rates in all available studies. 3 In patients with advanced-stage HL with positive interim FDG-PET results, treatment escalation has not proven to be beneficial, because studies showing

Full access


Plus Belinostat in Relapsed/Refractory non-Hodgkin Lymphoma Subtypes Charalambos Andreadis, MD, MSCE; UCSF Helen Diller Family Comprehensive Cancer Center: A Phase Ib Dose Escalation Trial of Carfilzomib in Combination with Bendamustine and Rituximab

Full access

The Role of Transplant in Multiple Myeloma

Matthew Mei and George Somlo

Intergroup Trial S9321 found no PFS or OS benefit with early ASCT, although most of the patients who experienced relapse while undergoing chemotherapy confirmed that delayed ASCT had an adverse effect on OS. 14 Tandem ASCT Tandem ASCT refers to a

Full access

New NCCN Guidelines: Smoking Cessation for Patients With Cancer

Peter G. Shields

added. With a couple more questions, the health care provider can quickly gauge the challenges for quitting and the risk of relapse. Then the algorithm provides guidance for evaluating Figure 1 Pharmacotherapy options for smoking cessation

Full access

New Treatment Options for the Management of Multiple Myeloma

Shaji K. Kumar

approaching MM is to make sure the diagnosis is correct. Identifying the time point for therapy is critical. Despite effective treatment, most patients will eventually relapse. Hopefully we can offer patients an extended, treatment-free interval,” Dr. Kumar

Full access

Non-Hodgkin's Lymphomas

Andrew D. Zelenetz, Jeremy S. Abramson, Ranjana H. Advani, C. Babis Andreadis, Nancy Bartlett, Naresh Bellam, John C. Byrd, Myron S. Czuczman, Luis E. Fayad, Martha J. Glenn, Jon P. Gockerman, Leo I. Gordon, Nancy Lee Harris, Richard T. Hoppe, Steven M. Horwitz, Christopher R. Kelsey, Youn H. Kim, Ann S. LaCasce, Auayporn Nademanee, Pierluigi Porcu, Oliver Press, Barbara Pro, Nashitha Reddy, Lubomir Sokol, Lode J. Swinnen, Christina Tsien, Julie M. Vose, William G. Wierda, Joachim Yahalom, and Nadeem Zafar

essentially eliminated because residual masses were defined as a partial or complete response based on the result of a PET scan. Using the revised system, response is categorized as complete response, partial response, stable disease, and relapsed disease or

Full access

Rational Use of Cytotoxic Chemotherapy for Recurrent Ovarian Cancer

Joyce Liu and Ursula Matulonis

of survival following second-line chemotherapy in small cell lung cancer and ovarian patients . Int J Oncol 1999 ; 15 : 1233 – 1238 . 7. Medical Research Council . OV05: A randomized trial in relapsed ovarian cancer: early treatment

Full access

Infectious Complications Associated With Immunomodulating Monoclonal Antibodies Used in the Treatment of Hematologic Malignancy

Sophia Koo and Lindsey R. Baden

. 17. Archimbaud C Bailly JL Chambon M . Molecular evidence of persistent echovirus 13 meningoencephalitis in a patient with relapsed lymphoma after an outbreak of meningitis in 2000 . J Clin Microbiol 2003 ; 41 : 4605 – 4610 . 18